Show simple item record

dc.contributor.authorTuñón Fernández, José Luis 
dc.contributor.authorCristóbal, Carmen
dc.contributor.authorTarín, Nieves
dc.contributor.authorAceña Navarro, Álvaro 
dc.contributor.authorGonzález Casaús, María Luisa
dc.contributor.authorHuelmos, Ana Isabel
dc.contributor.authorAlonso, Joaquín Jesus
dc.contributor.authorLorenzo González, Óscar 
dc.contributor.authorGonzález-Parra, Emilio
dc.contributor.authorMahillo, Ignacio
dc.contributor.authorPello, Ana María
dc.contributor.authorCarda, Rocío
dc.contributor.authorFarré, Jerónimo
dc.contributor.authorRodríguez Artalejo, Fernando 
dc.contributor.authorLópez Bescós, Lorenzo
dc.contributor.authorEgido, Jesús
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.contributor.otherUAM. Departamento de Medicina Preventiva y Salud Pública y Microbiologíaes_ES
dc.date.accessioned2015-06-24T08:08:52Z
dc.date.available2015-06-24T08:08:52Z
dc.date.issued2014-04-18
dc.identifier.citationPlos One 9.4 (2014): e95402en_US
dc.identifier.issn1932-6203 (online)en_US
dc.identifier.urihttp://hdl.handle.net/10486/667012
dc.description.abstractObjective: Vitamin D and fibroblast growth factor-23 (FGF-23) are related with cardiovascular disorders. We have investigated the relationship of calcidiol (vitamin D metabolite) and FGF-23 plasma levels with the incidence of adverse outcomes in patients with coronary artery disease. Methods: Prospective follow-up study of 704 outpatients, attending the departments of Cardiology of four hospitals in Spain, 6-12 months after an acute coronary event. Baseline calcidiol, FGF-23, parathormone, and phosphate plasma levels were assessed. The outcome was the development of acute ischemic events (any acute coronary syndrome, stroke, or transient ischemic attack), heart failure, or death. Cox regression adjusted for the main confounders was performed. Results: Calcidiol levels showed a moderate-severe decrease in 57.3% of cases. Parathormone, FGF-23, and phosphate levels were increased in 30.0%, 11.5% and 0.9% of patients, respectively. Only 22.4% of patients had glomerular filtration rate< 60 ml/min1.73 m2. After a mean follow-up was 2.15±0.99 years, 77 patients developed the outcome. Calcidiol (hazard ratio [HR] = 0.67; 95% confidence interval [CI] = 0.48-0.94; p = 0.021) and FGF-23 (HR = 1.13; 95% CI = 1.04-1.23; p = 0.005) plasma levels predicted independently the outcome. There was a significant interaction between calcidiol and FGF-23 levels (p = 0.025). When the population was divided according to FGF-23 levels, calcidiol still predicted the outcome independently in patients with FGF-23 levels higher than the median (HR = 0.50; 95% CI = 0.31-0.80; p = 0.003) but not in those with FGF-23 levels below this value (HR = 1.03; 95% CI = 0.62-1.71; p = 0.904). Conclusions: Abnormalities in mineral metabolism are frequent in patients with stable coronary artery disease. In this population, low calcidiol plasma levels predict an adverse prognosis in the presence of high FGF-23 levelsen_US
dc.description.sponsorshipThis work was supported by grants from the following: Fondo de Investigaciones Sanitarias (PI05/0451, PI05/1497, PI05/52475, PI05/1043, PS09/01405, and PI10/00072): http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml; Spanish Society of Cardiology; Spanish Heart Foundation. http://www.secardiologia.es/; Spanish Society of Arteriosclerosis. www.searteriosclerosis.org; RECAVA (RD06/0014/0035); www.recava.com; Fundación Lilly. https://www.lilly.es/nuestra-compania/fundacion-lilly-folder; Instituto de Salud Carlos III FEDER (FJD biobank: RD09/0076/00101); http://www.isciii.es/; and AbbVie Laboratories. http://www.abbvie.es/en_US
dc.format.extent9 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherPublic Library of Scienceen_US
dc.relation.ispartofPlos Oneen_US
dc.rights© 2014 Tuñón et al.es_ES
dc.subject.otherBiological Markersen_US
dc.subject.otherCoronary Artery Diseaseen_US
dc.subject.otherFibroblast Growth Factorsen_US
dc.subject.otherFollow-Up Studiesen_US
dc.subject.otherVitamin Den_US
dc.subject.otherPrognosisen_US
dc.titleCoexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery diseaseen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.identifier.doi10.1371/journal.pone.0095402es_ES
dc.identifier.publicationfirstpagee95402es_ES
dc.identifier.publicationissue4es_ES
dc.identifier.publicationlastpagee95402es_ES
dc.identifier.publicationvolume9es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen
dc.authorUAMAceña Navarro, Álvaro (279732)
dc.authorUAMRodríguez Artalejo, Fernando (259343)
dc.authorUAMTuñón Fernández, José Luis (258858)
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD)
dc.institutoUAMInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record